Liu Shuai, Liu Lei, Liu Zhuo, Zhang Fan, Ma Lulin, Tian Xiaojun, Hou Xiaofei, Wang Guoliang, Zhao Lei, Zhang Shudong
Department of Urology, Peking University Third Hospital, Beijing 100191, China.
Beijing Da Xue Xue Bao Yi Xue Ban. 2024 Dec 18;56(4):624-630. doi: 10.19723/j.issn.1671-167X.2024.04.013.
To analyze the clinicopathological features, prognostic value and surgical treatment experience in patients with adrenocortical carcinoma with venous tumor thrombus.
We collected relevant data of the patients with adrenocortical carcinoma who had undergone surgery in Peking University Third Hospital from 2018 to 2023. The patients were divided into venous tumor thrombus group and non-tumor thrombus group. The Wilcoxon rank sum test was used to compare the quantitative variables. The chi-squared test and Fisher's exact test were used to compare the categorical variables. The Kaplan-Meier method was used to estimate the survival rate.
A total of 27 patients with adrenocortical carcinoma were included, of whom 11 cases (40.7%) had venous tumor thrombus. In the patients with venous tumor thrombus, 8 patients were female and 3 were male. The median age was 49 (36, 58) years. The median body mass index was 26.0 (24.1, 30.4) kg/m. Seven patients presented with symptoms at their initial visit. Six patients had a history of hypertension. Elevated levels of cortisol were observed in 2 cases. Three tumors were found on the left side, while 8 were found on the right side. Median tumor diameter was 9.4 (6.5, 12.5) cm. On the left, there was a case of tumor thrombus limited to the central vein of the left adrenal gland without invasion into the left renal vein, and two cases of tumor thrombus growth extending into the inferior vena cava below the liver. One case of tumor thrombus on the right adrenal central vein did not invade the inferior vena cava. Four cases of tumor thrombus invaded the inferior vena cava below the liver and three cases extended to the posterior of the liver. Ten patients were in European Network for the Study of Adrenal Tumors (ENSAT) stage Ⅲ and one was in ENSAT stage Ⅳ. Open surgery was performed in 6 cases, laparoscopic surgery alone in 4 cases and robot-assisted laparoscopic surgery in 1 case. Two patients underwent ipsilateral kidney resection. Median operative time was 332 (261, 440) min. Median intraoperative bleeding was 900 (700, 2 200) mL. Median hospital stay was 9 (5, 10) days. Median survival time for the patients with tumor thrombus was 24.0 months and median time to recurrence was 7.0 months. The median survival and recurrence time of 16 patients without tumor thrombus were not reached. The patients with tumor thrombus had worse 3-year overall survival (OS) rate (40.9% . 71.4%; Log-rank, =0.038) and 2-year recurrence-free survival (RFS) (9.1% .53.7%; Log-rank, =0.015) rates compared with the patients with non-tumor thrombus.
Patients with adrenocortical carcinoma with venous tumor thrombus have poor prognosis. Different adrenal tumor resections and venous tumor thrombus removal procedures based on different tumor thrombus locations are safe and effective in treating this disease.
分析肾上腺皮质癌伴静脉瘤栓患者的临床病理特征、预后价值及手术治疗经验。
收集2018年至2023年在北京大学第三医院接受手术治疗的肾上腺皮质癌患者的相关资料。将患者分为静脉瘤栓组和无瘤栓组。采用Wilcoxon秩和检验比较定量变量。采用卡方检验和Fisher确切检验比较分类变量。采用Kaplan-Meier法估计生存率。
共纳入27例肾上腺皮质癌患者,其中11例(40.7%)有静脉瘤栓。有静脉瘤栓的患者中,女性8例,男性3例。中位年龄为49(36,58)岁。中位体重指数为26.0(24.1,30.4)kg/m。7例患者初诊时有症状。6例患者有高血压病史。2例患者皮质醇水平升高。左侧发现3个肿瘤,右侧发现8个肿瘤。中位肿瘤直径为9.4(6.5,12.5)cm。左侧有1例肿瘤栓子局限于左肾上腺中央静脉,未侵犯左肾静脉,2例肿瘤栓子生长延伸至肝下下腔静脉。右侧肾上腺中央静脉有1例肿瘤栓子未侵犯下腔静脉。4例肿瘤栓子侵犯肝下下腔静脉,3例延伸至肝后。10例患者处于欧洲肾上腺肿瘤研究网络(ENSAT)Ⅲ期,1例处于ENSATⅣ期。6例行开放手术,4例行单纯腹腔镜手术,1例行机器人辅助腹腔镜手术。2例患者行同侧肾切除术。中位手术时间为332(261,440)分钟。中位术中出血量为900(700,2200)mL。中位住院时间为9(5,10)天。有瘤栓患者的中位生存时间为24.0个月,中位复发时间为7.0个月。16例无瘤栓患者的中位生存和复发时间未达到。与无瘤栓患者相比,有瘤栓患者的3年总生存率(OS)(40.9%对71.4%;Log-rank,P = 0.038)和2年无复发生存率(RFS)(9.1%对53.7%;Log-rank,P = 0.015)更差。
肾上腺皮质癌伴静脉瘤栓患者预后较差。根据不同的肿瘤栓子位置采取不同的肾上腺肿瘤切除术和静脉瘤栓清除术治疗该病安全有效。